P.E. Hall

TL;DR: All three injectable regimens compare favourably with oral contraceptives in terms of pregnancy and total continuation rates observed in clinical trial settings and for family planning programs, NET-EN (60-day) has the advantage of low pregnancy rates compared to NET- EN (84-day), and a schedule of administration that does not change.

TL;DR: This new approach shifts attention from promotion of a particular technology to an emphasis on the method mix, the capacity to provide services with quality of care, reproductive choice, and users' perspectives and needs and suggests that technology choice should be undertaken through a participatory process.

TL;DR: Two dosages of depot-medroxyprogesterone acetate, 100 mg and 150 mg given every 90 days, were compared in two groups of women with regard to effectiveness, reported complaints and reasons for discontinuation, showing little difference in efficacy and side effects.

TL;DR: The data suggest that greater consideration be given to the benefits and risks of including progestogen-only oral contraceptives in the family planning programmes of some countries.

TL;DR: The analysis suggests how the life-table analysis of discontinuation reasons underestimates the true incidence of vaginal bleeding irregularities in a clinical trial.